Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Q Therapeutics selects Goodwin for antibody manufacturing
This IgM antibody recognizes a unique cell surface marker that is expressed on Q-Cells (neural glial cells). On successful completion of the production, Q Therapeutics will utilize the
This IgM antibody recognizes a unique cell surface marker that is expressed on Q-Cells (neural glial cells). On successful completion of the production, Q Therapeutics will utilize the
The FDA Center for Drug Evaluation and Research (CDER) acknowledged that complete response, which was the primary endpoint in the pivotal trial, was an appropriate endpoint for assessing
Under the agreement, both Innovative Biosensors (IBI) and Universal Detection Technology (UDT) will market and distribute their partner’s biodetection equipment, in addition to their own products, broadening their
Preliminary results from the first two of three cohorts demonstrate that the oral dosing regimens tested so far produce robust reductions in plasma viral load and are well
This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. CYT387 is claimed to possess an excellent selectivity profile
Under the terms of the agreement, Desitin will oversee, and be responsible for the expenses related to, all clinical development, regulatory approvals and commercialization efforts required to market
Results showed that 68% of the 25 patients who had received low-dose Gattex therapy and continued on low-dose Gattex, and 52% of the 27 patients who had received
The transaction, which is now subject to the necessary regulatory approvals, will include the transfer of the assets related to the acquired brands, as well as the employees
He replaces Dale Johnson, who retired in February, 2008. Mr Kullback brings almost 25 years of financial and management experience to Angeion. Most recently he was CFO of
The randomized, double-blind, vehicle-controlled study met its primary and secondary endpoints by demonstrating clear efficacy and safety in 482 patients. NanoBio’s uniquely formulated lotion has reportedly resulted in